FDA greenlights 1st drug to delay onset of Type 1 diabetes

In a win for Red Bank, N.J.-based ProventionBio, the FDA approved its drug Tzield Nov. 17, marking the first approved therapy to delay the onset of Type 1 diabetes. 

Tzield (teplizumab-mzwv) is approved for patients 8 years and older who currently have stage 2 Type 1 diabetes. In a trial of 76 patients with stage 2 type 1 diabetes, 45 percent of patients who received the injection later developed stage 3 compared to 72 percent of patients who received the placebo, according to the FDA. 

"The drug's potential to delay clinical diagnosis of Type 1 diabetes may provide patients with months to years without the burdens of disease," John Sharretts, MD, director of the FDA's division of diabetes, lipid disorders and obesity, said in a statement. 

Type 1 and Type 2 diabetes, a chronic disease in which the body cannot produce enough insulin, were the direct cause of 1.5 million deaths in 2019, according to the World Health Organization

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like

Thank you so much for your interest in our content. Please register to access this complimentary archived content. By registering, you will receive our newsletter which can be opted out of at any time.

 

 

Already Registered? Click here to confirm.